Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INB 619

Next Previous
Drug Profile

INB 619

Alternative Names: INB-619

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IN8bio
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; B-cell lymphoma

Most Recent Events

  • 19 Dec 2025 IN8bio intends to meet with the US FDA for the discussion for the IND application of INB 619 in Cancer and Autoimmune diseases in 2026
  • 19 Dec 2025 IN8bio announces intention to submit an Investigational New Drug application (IND) to the US FDA for B-cell lymphoma and Autoimmune disorders in 2027
  • 06 Dec 2025 Pharmacokinetics and pharmacodynamics data from a preclinical studies in B-cell lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top